{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:08:05Z","timestamp":1789733285697,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI151006"],"award-info":[{"award-number":["1R01AI151006"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI151006"],"award-info":[{"award-number":["1R01AI151006"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI151006"],"award-info":[{"award-number":["1R01AI151006"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A Crimean-Congo hemorrhagic fever virus replicon particle vaccine was evaluated for long-term immunity and efficacy in mice. IgG responses persisted up to 18 months, with similar titers across dosing strategies through 12 months. Protective efficacy reached \u226575% at 6 months (prime-only) and up to 12 months (prime-boost). Booster dosing enhanced antibody avidity, effector function, and improved long-term protection. These findings support durable immunity from single or boosted vaccination.<\/jats:p>","DOI":"10.1038\/s41541-025-01293-9","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:01:23Z","timestamp":1763730083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Durable humoral immunity and long-term protection induced by a Crimean-Congo hemorrhagic fever virus replicon particle vaccine in mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Teresa E.","family":"Sorvillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Karaaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florine E. M.","family":"Scholte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn D.","family":"Coleman-McCray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Aida-Ficken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Pegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina F.","family":"Spiropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1293_CR1","unstructured":"WHO. WHO | List of Blueprint priority diseases. WHO (2018)."},{"key":"1293_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1473-3099(06)70435-2","volume":"6","author":"\u00d6 Erg\u00f6n\u00fcl","year":"2006","unstructured":"Erg\u00f6n\u00fcl, \u00d6 Crimean-Congo haemorrhagic fever. Lancet Infect. Dis. 6, 203\u2013214 (2006).","journal-title":"Lancet Infect. Dis."},{"key":"1293_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3201\/eid1804.111374","volume":"18","author":"H Bodur","year":"2012","unstructured":"Bodur, H., Akinci, E., Ascioglu, S., \u00d6ng\u00fcr\u00fc, P. & Uyar, Y. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg. Infect. Dis. 18, 640\u2013642 (2012).","journal-title":"Emerg. Infect. Dis."},{"key":"1293_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","volume":"100","author":"DA Bente","year":"2013","unstructured":"Bente, D. A. et al. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antivir. Res 100, 159\u2013189 (2013).","journal-title":"Antivir. Res"},{"key":"1293_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/14760584.2024.2331065","volume":"23","author":"VM Vashishtha","year":"2024","unstructured":"Vashishtha, V. M. & Kumar, P. The durability of vaccine-induced protection: an overview. Expert Rev. Vaccines 23, 389\u2013408 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"1293_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/22221751.2019.1601030","volume":"8","author":"FEM Scholte","year":"2019","unstructured":"Scholte, F. E. M. et al. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. Emerg. Microbes Infect. 8, 575\u2013578 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"1293_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00877-1","volume":"9","author":"TE Sorvillo","year":"2024","unstructured":"Sorvillo, T. E. et al. Replicon particle vaccination induces non-neutralizing anti-nucleoprotein antibody-mediated control of Crimean-Congo hemorrhagic fever virus. NPJ Vaccines 9, 88 (2024).","journal-title":"NPJ Vaccines"},{"key":"1293_CR8","doi-asserted-by":"crossref","unstructured":"Scholte, F. E. M. et al. Vaccination with the Crimean-Congo hemorrhagic fever virus viral replicon vaccine induces NP-based T-cell activation and antibodies possessing Fc-mediated effector functions. Front. Cell Infect Microbiol. 13, 1233148 (2023).","DOI":"10.3389\/fcimb.2023.1233148"},{"key":"1293_CR9","doi-asserted-by":"crossref","unstructured":"Welch, S. R. et al. Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination. Sci. Adv 9, eadh4057 (2023).","DOI":"10.1126\/sciadv.adh4057"},{"key":"1293_CR10","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/infdis\/jiy123","volume":"217","author":"MH Kainulainen","year":"2018","unstructured":"Kainulainen, M. H. et al. Use of a scalable replicon-particle vaccine to protect against lethal Lassa virus infection in the guinea pig model. J. Infect. Dis. 217, 1957\u20131966 (2018).","journal-title":"J. Infect. Dis."},{"key":"1293_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104573","volume":"170","author":"JR Spengler","year":"2019","unstructured":"Spengler, J. R. et al. Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine. Antivir. Res 170, 104573 (2019).","journal-title":"Antivir. Res"},{"key":"1293_CR12","doi-asserted-by":"crossref","unstructured":"Spengler, J. R. et al. Lassa virus replicon particle vaccine protects strain 13\/N guinea pigs against challenge with geographically and genetically diverse viral strains. J. Infect. Dis. 226, 1545\u20131550 (2022).","DOI":"10.1093\/infdis\/jiac028"},{"key":"1293_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105090","volume":"191","author":"JR Spengler","year":"2021","unstructured":"Spengler, J. R. et al. Viral replicon particles protect IFNAR-\/- mice against lethal Crimean-Congo hemorrhagic fever virus challenge three days after vaccination. Antivir. Res. 191, 105090 (2021).","journal-title":"Antivir. Res."},{"key":"1293_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46110-4","volume":"15","author":"AR Garrison","year":"2024","unstructured":"Garrison, A. R. et al. Nucleocapsid protein-specific monoclonal antibodies protect mice against Crimean-Congo hemorrhagic fever virus. Nat. Commun. 15, 1722 (2024).","journal-title":"Nat. Commun."},{"key":"1293_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53362-7","volume":"15","author":"SS Leventhal","year":"2024","unstructured":"Leventhal, S. S. et al. Antibodies targeting the Crimean-Congo Hemorrhagic fever virus nucleoprotein protect via TRIM21. Nat. Commun. 15, 9236 (2024).","journal-title":"Nat. Commun."},{"key":"1293_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00931-y","volume":"9","author":"E Karaaslan","year":"2024","unstructured":"Karaaslan, E. et al. Crimean Congo hemorrhagic fever virus nucleoprotein and GP38 subunit vaccine combination prevents morbidity in mice. NPJ Vaccines 9, 148 (2024).","journal-title":"NPJ Vaccines"},{"key":"1293_CR17","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1016\/j.vaccine.2012.08.003","volume":"30","author":"M Mousavi-Jazi","year":"2012","unstructured":"Mousavi-Jazi, M., Karlberg, H., Papa, A., Christova, I. & Mirazimi, A. Healthy individuals\u2019 immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine 30, 6225\u20136229 (2012).","journal-title":"Vaccine"},{"key":"1293_CR18","doi-asserted-by":"crossref","unstructured":"Canakoglu, N. et al. Immunization of Knock-Out \u03b1\/\u03b2 interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS Negl. Trop. Dis. 9, e0003579 (2015).","DOI":"10.1371\/journal.pntd.0003579"},{"key":"1293_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1089\/vbz.2015.1855","volume":"15","author":"J Kortekaas","year":"2015","unstructured":"Kortekaas, J. et al. Crimean-Congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice. Vector-Borne Zoonotic Dis. 15, 759\u2013764 (2015).","journal-title":"Vector-Borne Zoonotic Dis."},{"key":"1293_CR20","doi-asserted-by":"publisher","first-page":"e0005908","DOI":"10.1371\/journal.pntd.0005908","volume":"11","author":"AR Garrison","year":"2017","unstructured":"Garrison, A. R. et al. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Negl. Trop. Dis. 11, e0005908 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1293_CR21","doi-asserted-by":"publisher","unstructured":"Hawman, D. W. et al. Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.016 (2022).","DOI":"10.1016\/j.ymthe.2022.09.016"},{"key":"1293_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41564-020-00815-6","volume":"6","author":"DW Hawman","year":"2021","unstructured":"Hawman, D. W. et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model. Nat. Microbiol. 6, 187\u2013195 (2021).","journal-title":"Nat. Microbiol."},{"key":"1293_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/jmv.24400","volume":"88","author":"A Papa","year":"2016","unstructured":"Papa, A., Pappa, S., Panayotova, E., Papadopoulou, E. & Christova, I. Molecular epidemiology of Crimean-Congo hemorrhagic fever in Bulgaria-An update. J. Med. Virol. 88, 769\u2013773 (2016).","journal-title":"J. Med. Virol."},{"key":"1293_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.106045","volume":"233","author":"A Kleymann","year":"2025","unstructured":"Kleymann, A. et al. Crimean-Congo hemorrhagic fever virus replicon particle vaccine is safe and elicits functional, non-neutralizing anti-nucleoprotein antibodies and T cell activation in rhesus macaques. Antivir. Res. 233, 106045 (2025).","journal-title":"Antivir. Res."},{"key":"1293_CR25","doi-asserted-by":"publisher","unstructured":"Kainulainen, M. H. et al. Protection from lethal Lassa disease can be achieved both before and after virus exposure by administration of single-cycle replicating Lassa virus replicon particles. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiz284 (2019).","DOI":"10.1093\/infdis\/jiz284"},{"key":"1293_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/icb.2016.65","volume":"94","author":"AM Collins","year":"2016","unstructured":"Collins, A. M. IgG subclass co-expression brings harmony to the quartet model of murine IgG function. Immunol. Cell Biol. 94, 949\u2013954 (2016).","journal-title":"Immunol. Cell Biol."},{"key":"1293_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2427782","volume":"13","author":"TE Sorvillo","year":"2024","unstructured":"Sorvillo, T. E. et al. Inflammation associated with monocyte\/macrophage activation and recruitment corresponds with lethal outcome in a mouse model of Crimean-Congo haemorrhagic fever. Emerg. Microbes Infect. 13, 2427782 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"1293_CR28","doi-asserted-by":"publisher","first-page":"e2449182","DOI":"10.1001\/jamanetworkopen.2024.49182","volume":"7","author":"P Pitisuttithum","year":"2024","unstructured":"Pitisuttithum, P. et al. Pertussis immunity 5 years after booster vaccination with recombinant pertussis vaccines. JAMA Netw. Open 7, e2449182 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1293_CR29","doi-asserted-by":"publisher","first-page":"e2231778","DOI":"10.1001\/jamanetworkopen.2022.31778","volume":"5","author":"M Gilboa","year":"2022","unstructured":"Gilboa, M. et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 Omicron infection. JAMA Netw. Open 5, e2231778 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1293_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun, L., Su, Y., Jiao, A., Wang, X. & Zhang, B. T cells in health and disease. Signal Transduct. Target Ther. 8, 235 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1293_CR31","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1016\/j.vaccine.2014.08.028","volume":"32","author":"G Wong","year":"2014","unstructured":"Wong, G. et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 32, 5722\u20135729 (2014).","journal-title":"Vaccine"},{"key":"1293_CR32","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/S2666-5247(23)00001-0","volume":"4","author":"A Marzi","year":"2023","unstructured":"Marzi, A. et al. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques. Lancet Microbe 4, e171\u2013e178 (2023).","journal-title":"Lancet Microbe"},{"key":"1293_CR33","doi-asserted-by":"publisher","first-page":"e94355","DOI":"10.1371\/journal.pone.0094355","volume":"9","author":"CE Mire","year":"2014","unstructured":"Mire, C. E. et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS ONE 9, e94355 (2014).","journal-title":"PLoS ONE"},{"key":"1293_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0104-x","volume":"4","author":"DR Stein","year":"2019","unstructured":"Stein, D. R. et al. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines 4, 8 (2019).","journal-title":"NPJ Vaccines"},{"key":"1293_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164946","volume":"133","author":"C Woolsey","year":"2023","unstructured":"Woolsey, C. et al. Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease. J. Clin. Investig. 133, e164946 (2023).","journal-title":"J. Clin. Investig."},{"key":"1293_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01045-1","volume":"9","author":"SS Leventhal","year":"2024","unstructured":"Leventhal, S. S. et al. Replicating RNA vaccine confers durable immunity against Crimean Congo hemorrhagic fever virus challenge in mice. NPJ Vaccines 9, 249 (2024).","journal-title":"NPJ Vaccines"},{"key":"1293_CR37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method for estimating fifty percent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"1293_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45740-w","volume":"13","author":"KA Davies","year":"2023","unstructured":"Davies, K. A. et al. Optimal reference genes for RNA tissue analysis in small animal models of hemorrhagic fever viruses. Sci. Rep. 13, 19384 (2023).","journal-title":"Sci. Rep."},{"key":"1293_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jim.2012.09.008","volume":"387","author":"G Almanzar","year":"2013","unstructured":"Almanzar, G., Ottensmeier, B., Liese, J. & Prelog, M. Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate. J. Immunol. Methods 387, 36\u201342 (2013).","journal-title":"J. Immunol. Methods"},{"key":"1293_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.07.002","volume":"473","author":"S Fischinger","year":"2019","unstructured":"Fischinger, S. et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods 473, 112630 (2019).","journal-title":"J. Immunol. Methods"},{"key":"1293_CR41","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3389\/fimmu.2019.01851","volume":"10","author":"AL Butler","year":"2019","unstructured":"Butler, A. L., Fallon, J. K. & Alter, G. A sample-sparing multiplexed ADCP Assay. Front. Immunol. 10, 1851 (2019).","journal-title":"Front. Immunol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01293-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01293-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01293-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:01:24Z","timestamp":1763730084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01293-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01293-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work the author(s) used ChatGPT selectively to improve grammar and syntax. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"244"}}